

**Anti-Keap1 Picoband Antibody**  
Catalog # ABO12448**Specification**

---

**Anti-Keap1 Picoband Antibody - Product Information**

Application	WB
Primary Accession	<a href="#">Q14145</a>
Host	Rabbit
Reactivity	Human
Clonality	Polyclonal
Format	Lyophilized

**Description**

Rabbit IgG polyclonal antibody for Kelch-like ECH-associated protein 1(KEAP1) detection. Tested with WB in Human.

**Reconstitution**

Add 0.2ml of distilled water will yield a concentration of 500ug/ml.

**Anti-Keap1 Picoband Antibody - Additional Information**

**Gene ID** 9817

**Other Names**

Kelch-like ECH-associated protein 1, Cytosolic inhibitor of Nrf2, INrf2, Kelch-like protein 19, KEAP1, INRF2, KIAA0132, KLHL19

**Calculated MW**

69666 MW KDa

**Application Details**

Western blot, 0.1-0.5 µg/ml, Human<br>

**Subcellular Localization**

Cytoplasm. Nucleus. Shuttles between cytoplasm and nucleus.

**Tissue Specificity**

Broadly expressed, with highest levels in skeletal muscle. .

**Protein Name**

Kelch-like ECH-associated protein 1

**Contents**

Each vial contains 5mg BSA, 0.9mg NaCl, 0.2mg Na<sub>2</sub>HPO<sub>4</sub>, 0.05mg Na<sub>3</sub>.

**Immunogen**

E.coli-derived human Keap1 recombinant protein (Position: E25-E205). Human Keap1 shares 96.7% and 97.2% amino acid (aa) sequence identity with mouse and rat Keap1, respectively.

**Purification**

Immunogen affinity purified.

### Cross Reactivity

No cross reactivity with other proteins.

### Storage

**At -20°C for one year. After reconstitution, at 4°C for one month. It can also be aliquotted and stored frozen at -20°C for a longer time. Avoid repeated freezing and thawing.**

## Anti-Keap1 Picoband Antibody - Protein Information

**Name** KEAP1 {ECO:0000303|PubMed:14585973, ECO:0000312|HGNC:HGNC:23177}

### Function

Substrate-specific adapter of a BCR (BTB-CUL3-RBX1) E3 ubiquitin ligase complex that regulates the response to oxidative stress by targeting NFE2L2/NRF2 for ubiquitination (PubMed: <a href="http://www.uniprot.org/citations/14585973" target="\_blank">14585973</a>, PubMed: <a href="http://www.uniprot.org/citations/15379550" target="\_blank">15379550</a>, PubMed: <a href="http://www.uniprot.org/citations/15572695" target="\_blank">15572695</a>, PubMed: <a href="http://www.uniprot.org/citations/15601839" target="\_blank">15601839</a>, PubMed: <a href="http://www.uniprot.org/citations/15983046" target="\_blank">15983046</a>, PubMed: <a href="http://www.uniprot.org/citations/37339955" target="\_blank">37339955</a>). KEAP1 acts as a key sensor of oxidative and electrophilic stress: in normal conditions, the BCR(KEAP1) complex mediates ubiquitination and degradation of NFE2L2/NRF2, a transcription factor regulating expression of many cytoprotective genes (PubMed: <a href="http://www.uniprot.org/citations/15601839" target="\_blank">15601839</a>, PubMed: <a href="http://www.uniprot.org/citations/16006525" target="\_blank">16006525</a>). In response to oxidative stress, different electrophile metabolites trigger non-enzymatic covalent modifications of highly reactive cysteine residues in KEAP1, leading to inactivate the ubiquitin ligase activity of the BCR(KEAP1) complex, promoting NFE2L2/NRF2 nuclear accumulation and expression of phase II detoxifying enzymes (PubMed: <a href="http://www.uniprot.org/citations/16006525" target="\_blank">16006525</a>, PubMed: <a href="http://www.uniprot.org/citations/17127771" target="\_blank">17127771</a>, PubMed: <a href="http://www.uniprot.org/citations/18251510" target="\_blank">18251510</a>, PubMed: <a href="http://www.uniprot.org/citations/19489739" target="\_blank">19489739</a>, PubMed: <a href="http://www.uniprot.org/citations/29590092" target="\_blank">29590092</a>). In response to selective autophagy, KEAP1 is sequestered in inclusion bodies following its interaction with SQSTM1/p62, leading to inactivation of the BCR(KEAP1) complex and activation of NFE2L2/NRF2 (PubMed: <a href="http://www.uniprot.org/citations/20452972" target="\_blank">20452972</a>). The BCR(KEAP1) complex also mediates ubiquitination of SQSTM1/p62, increasing SQSTM1/p62 sequestering activity and degradation (PubMed: <a href="http://www.uniprot.org/citations/28380357" target="\_blank">28380357</a>). The BCR(KEAP1) complex also targets BPTF and PGAM5 for ubiquitination and degradation by the proteasome (PubMed: <a href="http://www.uniprot.org/citations/15379550" target="\_blank">15379550</a>, PubMed: <a href="http://www.uniprot.org/citations/17046835" target="\_blank">17046835</a>).

### Cellular Location

Cytoplasm. Nucleus. Note=Mainly cytoplasmic (PubMed:15601839). In response to selective autophagy, relocalizes to inclusion bodies following interaction with SQSTM1/p62 (PubMed:20452972).

### Tissue Location


Broadly expressed, with highest levels in skeletal muscle.

## Anti-Keap1 Picoband Antibody - Protocols

Provided below are standard protocols that you may find useful for product applications.

- [Western Blot](#)
- [Blocking Peptides](#)
- [Dot Blot](#)
- [Immunohistochemistry](#)
- [Immunofluorescence](#)
- [Immunoprecipitation](#)
- [Flow Cytometry](#)
- [Cell Culture](#)

## Anti-Keap1 Picoband Antibody - Images



Anti- Keap1 Picoband antibody, ABO12448, Western blotting All lanes: Anti Keap1 (ABO12448) at 0.5ug/ml Lane 1: HELA Whole Cell Lysate at 40ug Lane 2: MCF-7 Whole Cell Lysate at 40ug Lane 3: SW620 Whole Cell Lysate at 40ug Predicted bind size: 70KD Observed bind size: 70KD

## Anti-Keap1 Picoband Antibody - Background

KEAP1 (KELCH-LIKE ECH-ASSOCIATED PROTEIN 1), is a protein that in humans is encoded by the Keap1 gene. The KIAA0132 gene is mapped on 19p13.2. Keap1 contains a central BTB/POZ domain and a C-terminal double glycine repeat (DGR), or Kelch, module. Keap1 has been shown to interact with Nrf2, a master regulator of the antioxidant response, which is important for the amelioration of oxidative stress. In the presence of the electrophilic agent diethylmalate, Nrf2 activity is released from Keap1 and Nrf2 translocate to the nucleus. Under quiescent conditions, Nrf2 is anchored in the cytoplasm through binding to Keap1, which, in turn, facilitates the ubiquitination and subsequent proteolysis of Nrf2. Because Nrf2 activation leads to a coordinated antioxidant and anti-inflammatory response, and Keap1 represses Nrf2 activation, Keap1 has become a very attractive drug target.